Age-related incidence of acute hepatitis A in adult aged 20–59 years.

<p>Age-related incidence of acute hepatitis A in adult aged 20–59 years.</p

Monthly occurrence of acute hepatitis A from 2009 to 2013.

<p>Monthly occurrence of acute hepatitis A from 2009 to 2013.</p

Incidence of acute hepatitis A by age group from 2009 to 2013 according to National Health Insurance data; KO2011~2013, Korean Statistical Information Service data from 2011 to 2013.

<p>Incidence of acute hepatitis A by age group from 2009 to 2013 according to National Health Insurance data; KO2011~2013, Korean Statistical Information Service data from 2011 to 2013.</p

Disease burden of acute hepatitis A from 2009 to 2013: Severity and NHI-covered medical cost stratified by age group.

<p>Disease burden of acute hepatitis A from 2009 to 2013: Severity and NHI-covered medical cost stratified by age group.</p

Age-stratified anti-HAV IgG seropositivity from 2010 to 2014.

<p>Age-stratified anti-HAV IgG seropositivity from 2010 to 2014.</p

DataSheet_1_Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.docx

BackgroundThe assessment of long-term humoral and cellular immunity post-vaccination is crucial for establishing an optimal vaccination strategy.MethodsThis prospective cohort study evaluated adults (≥18 years) who received a BA.4/5 bivalent vaccine. We measured the anti-receptor binding domain immunoglobulin G antibody and neutralizing antibodies (NAb) against wild-type and Omicron subvariants (BA.5, BQ.1.1, BN.1, XBB.1 and EG.5) up to 9 months post-vaccination. T-cell immune responses were measured before and 4 weeks after vaccination.ResultsA total of 108 (28 SARS-CoV-2-naïve and 80 previously infected) participants were enrolled. Anti-receptor binding domain immunoglobulin G (U/mL) levels were higher at 9 months post-vaccination than baseline in SAR-CoV-2-naïve individuals (8,339 vs. 1,834, p6 cells) was highly cross-reactive at both baseline (wild-type/BA.5/XBB.1.5, 38.3/52.5/45.0 in SARS-CoV-2-naïve individuals; 51.6/54.9/54.9 in SARS-CoV-2-infected individuals) and 4 weeks post-vaccination, with insignificant boosting post-vaccination.ConclusionRemarkable cross-reactive neutralization was observed against BQ.1.1, BN.1, and XBB.1 up to 9 months after BA.4/5 bivalent vaccination, but not against EG.5. The T-cell immune response was highly cross-reactive.</p

Age-stratified incidence (per 100,000 persons per year) and case-fatality rate of invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and community-acquired pneumonia (CAP).

<p>Age-stratified incidence (per 100,000 persons per year) and case-fatality rate of invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and community-acquired pneumonia (CAP).</p

Age-stratified incidence (per 100,000 persons per year) and case-fatality rate of invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and community-acquired pneumonia (CAP).

<p>Age-stratified incidence (per 100,000 persons per year) and case-fatality rate of invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and community-acquired pneumonia (CAP).</p

Year- and age-dependent trend analysis—Proportion of pneumococcal pneumonia (PP) among community-acquired pneumonia (CAP).

<p>Year- and age-dependent trend analysis—Proportion of pneumococcal pneumonia (PP) among community-acquired pneumonia (CAP).</p